This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

John McDonald
Corporate VP, Global R&D Business Development at Novo Nordisk


John McDonald joined Novo Nordisk in October 2018. Prior to Novo Nordisk, John held various senior roles at Biogen, Inc., MPM Capital, Genzyme Corporation, Millennium Pharmaceuticals, and Genentech.

In his career, John was a Co-Founder of Solasia Pharma KK, a public oncology-focused company traded on Tokyo's Mothers Stock Exchange, and has led or participated in the evaluation, structuring and negotiating of numerous mergers and acquisitions, licenses and strategic alliances, e.g., Biogen’s recent collaborations with Ionis Pharmaceuticals (including the April 2018, $1 Billion upfront drug discovery relationship), Mitsubishi Tanabe, AGTC, Sangamo BioSciences, Portola Pharmaceuticals, Inc., partnering Biogen's marketed products with UCB in China, Biogen’s acquisition of Stromedix, Inc., Millennium's Ex-U.S. collaboration with Ortho Biotech/Johnson & Johnson for VELCADE, the restructuring of Millennium's relationship with Schering-Plough Corp. for INTEGRILIN, the sale of Millennium's interest in its CAMPATH joint venture, Genzyme’s alliance with BioMarin for ALDURAZYME, and Genentech’s alliances with Xoma Corporation (RAPTIVA) and IDEC Pharmaceuticals (RITUXAN).

Agenda Sessions

  • Dual Dialogue: RNAi Discovery and Development Collaboration Case Study

  • LIVE Q&A SESSION: Dual Dialogue: RNAi Discovery and Development Collaboration Case Study